Measurement and Analysis of Patient Reported Gastrointestinal (GI) and Health-Related Quality of Life (HRQL) Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate (MPA).
Phase of Trial: Phase III
Latest Information Update: 20 Apr 2011
At a glance
- Drugs Mycophenolate sodium (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 16 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Jun 2009 Planned end date changed from 1 Dec 2008 to 1 Jun 2009 as reported by ClinicalTrials.gov record.
- 03 Jul 2008 New trial record.